Investigating the high energy QCD approaches for prompt photon production at the LHC

We investigate the rapidity and transverse momentum distributions of the prompt photon production at the CERN LHC energies considering the current perturbative QCD approaches for this scattering process. Namely, we compare the predictions from the usual NLO pQCD calculations to the the color dipole formalism, using distinct dipole cross sections. Special attention is paid to parton saturation models at high energies, which are expected to be important at the forward rapidities in pp collisions at the LHC.Comment: Contribution to the proceedings of the 3rd International Conference on Hard and Electro-Magnetic Probes of High-Energy Nuclear Collisions (Hard Probes 2008), 8-14 June 2008, Illa da Toxa (Galicia-Spain). Talk presented by M.V.T. Machad

Hard diffractive quarkonium hadroproduction at high energies

We present a study of heavy quarkonium production in hard diffractive process by the Pomeron exchange for Tevatron and LHC energies. The numerical results are computed using recent experimental determination of the diffractive parton density functions in Pomeron and are corrected by unitarity corrections through gap survival probability factor. We give predictions for single as well as central diffractive ratios. These processes are sensitive to the gluon content of the Pomeron at small Bjorken-x and may be particularly useful in studying the small-x physics. They may also be a good place to test the different available mechanisms for quarkonium production at hadron colliders.Comment: 7 pages, 3 figures, 1 table. Final version to be published in European Physical Journal

Comorbidity-Adjusted life expectancy: A new tool to inform recommendations for optimal screening strategies

Background: Many guidelines recommend considering health status and life expectancy when making cancer screening decisions for elderly persons. Objective: To estimate life expectancy for elderly persons without a history of cancer, taking into account comorbid conditions. Design: Population-based cohort study. Setting: A 5% sample of Medicare beneficiaries in selected geographic areas, including their claims and vital status information. Participants: Medicare beneficiaries aged 66 years or older between 1992 and 2005 without a history of cancer (n = 407 749). Measurements: Medicare claims were used to identify comorbid conditions included in the Charlson index. Survival probabilities were estimated by comorbidity group (no, low/medium, and high) and for the 3 most prevalent conditions (diabetes, chronic obstructivepulmonary disease, and congestive heart failure) by using the Cox proportional hazards model. Comorbidity-adjusted life expectancy was calculated based on comparisons of survival models with U.S. life tables. Survival probabilities from the U.S. life tables providing the most similar survival experience to the cohort of interest were used.Results: Persons with higher levels of comorbidity had shorter life expectancies, whereas those with no comorbid conditions, including very elderly persons, had favorable life expectancies relative to an average person of the same chronological age. The estimated life expectancy at age 75 years was approximately 3 years longer for persons with no comorbid conditions and approximately 3 years shorter for those with high comorbidity relative to the average U.S. population. Limitations: The cohort was limited to Medicare fee-for-service beneficiaries aged 66 years or older living in selected geographic areas. Data from the Surveillance, Epidemiology, and End Results cancer registry and Medicare claims lack information on functional status and severity of comorbidity, which might influence life expectancy in elderly persons. Conclusion: Life expectancy varies considerably by comorbidity status in elderly persons. Comorbidity-adjusted life expectancy may help physicians tailor recommendations for stopping or continuing cancer screening for individual patients. Primary Funding Source: None